SELLAS Life Sciences (SLS) Goodwill & Intangibles (2011 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Goodwill & Intangibles of $1.9 million for Q1 2026, little changed year-over-year from $1.9 million in Q1 2025, and little changed quarter-over-quarter from $1.9 million in Q4 2025.
Analysis
SELLAS Life Sciences (SLS) Goodwill & Intangibles (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Goodwill & Intangibles for 16 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles changed 0.0% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (changed 0.0% YoY), while the FY2025 annual figure was $1.9 million, changed 0.0% from the prior year.
- Goodwill & Intangibles held at $1.9 million in Q1 2026 per SLS's latest filing, from $1.9 million in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $1.9 million in Q1 2022 and bottomed at $1.9 million in Q4 2023.
- Historically, Goodwill & Intangibles has averaged $1.9 million across 5 years, with a median of $1.9 million in 2022.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles advanced 0.74% — and 2023, when it dropped 0.73%.
- SELLAS Life Sciences' Goodwill & Intangibles stood at $1.9 million in 2022, then fell by 0.73% to $1.9 million in 2023, then climbed by 0.74% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
- Business Quant data shows SLS's Goodwill & Intangibles at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.91 Mn |
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Jun 30, 2023 | 1.91 Mn |
| Mar 31, 2023 | 1.91 Mn |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 1.91 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.91 Mn |
| Sep 30, 2021 | 1.91 Mn |